ATE320184T1 - Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane - Google Patents

Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane

Info

Publication number
ATE320184T1
ATE320184T1 AT99914103T AT99914103T ATE320184T1 AT E320184 T1 ATE320184 T1 AT E320184T1 AT 99914103 T AT99914103 T AT 99914103T AT 99914103 T AT99914103 T AT 99914103T AT E320184 T1 ATE320184 T1 AT E320184T1
Authority
AT
Austria
Prior art keywords
upper respiratory
treatment
respiratory organs
xylitol
xylitol compositions
Prior art date
Application number
AT99914103T
Other languages
English (en)
Inventor
Alonzo H Jones
Original Assignee
Alonzo H Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26761708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE320184(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alonzo H Jones filed Critical Alonzo H Jones
Application granted granted Critical
Publication of ATE320184T1 publication Critical patent/ATE320184T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99914103T 1998-03-24 1999-03-24 Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane ATE320184T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7918498P 1998-03-24 1998-03-24
US09/220,283 US6054143A (en) 1998-03-24 1998-12-23 Xylitol delivery

Publications (1)

Publication Number Publication Date
ATE320184T1 true ATE320184T1 (de) 2006-04-15

Family

ID=26761708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914103T ATE320184T1 (de) 1998-03-24 1999-03-24 Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane

Country Status (16)

Country Link
US (2) US6054143A (de)
EP (1) EP1063885B1 (de)
JP (1) JP2002507548A (de)
CN (1) CN1302183A (de)
AT (1) ATE320184T1 (de)
AU (1) AU748327B2 (de)
CA (1) CA2321819C (de)
DE (1) DE69930375T2 (de)
DK (1) DK1063885T3 (de)
ES (1) ES2161666T3 (de)
IL (1) IL138467A0 (de)
NO (1) NO331654B1 (de)
NZ (1) NZ506557A (de)
PT (1) PT1063885E (de)
TR (1) TR200002739T2 (de)
WO (1) WO1999048361A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054143A (en) * 1998-03-24 2000-04-25 Jones; Alonzo H. Xylitol delivery
JP2002532520A (ja) * 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
US6716819B2 (en) * 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
JP2001354549A (ja) * 2000-06-08 2001-12-25 Koike Kagaku Kk 鼻腔洗浄エアゾール製品
US6596284B1 (en) * 2002-04-30 2003-07-22 Thomas E. Fleming Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers
US20040039042A1 (en) * 2002-08-23 2004-02-26 Fleming Thomas E. Method of transdermal drug delivery
US20040228804A1 (en) * 2003-05-16 2004-11-18 Jones Alonzo H. Nasal administration of xylitol to a non-human mammal
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
EP1786436B1 (de) * 2004-04-29 2012-11-14 RiboCor, Inc. Verfahren für verbesserung der atmungseffizienz
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US20060034947A1 (en) * 2004-06-02 2006-02-16 Burr James B Erythritol compositions for nasopharynx cleansing
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
BRPI0608691A2 (pt) * 2005-03-10 2010-12-07 3M Innovative Properties Company composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição
EP1858482B1 (de) * 2005-03-10 2014-04-23 3M Innovative Properties Company Verfahren zur reduktion von mikrobieller kontamination
US20060275223A1 (en) * 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
WO2007032962A2 (en) * 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
EP1775306B1 (de) * 2005-10-11 2009-04-08 Johnson & Johnson Consumer France SAS ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung
US8337906B2 (en) * 2006-07-25 2012-12-25 Zinreich James Nasal composition
US20080026078A1 (en) * 2006-07-25 2008-01-31 Zinreich James Nasal composition
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
CN102462728A (zh) * 2010-11-17 2012-05-23 郭进军 一种治疗和预防细菌性上呼吸道感染的药物组合物
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
EP2854781A4 (de) 2012-05-25 2016-04-13 Xlear Inc Xylitolbasierte antimukosale zusammensetzungen sowie damit verbundene verfahren und zusammensetzungen
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
CN103893158A (zh) * 2014-04-24 2014-07-02 山东福田药业有限公司 木糖醇在雾霾性呼吸系统疾病中的应用
CN105326786A (zh) * 2015-11-09 2016-02-17 合肥九研医药科技开发有限公司 一种鼻腔冲洗液组合物及其制备方法
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
WO2017103348A1 (fr) 2015-12-17 2017-06-22 Urgo Recherche Innovation Et Developpement Composition liquide pour son utilisation comme solution nasale
US10959450B2 (en) * 2017-10-15 2021-03-30 Yu Heong Jun Food composition for relieving symptoms of allergic and autoimmune diseases
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
FR3088193B1 (fr) 2018-11-13 2021-01-22 Andrea Fox Composition aqueuse, son procede de fabrication, et dispositif d’administration nasal
US10874650B1 (en) * 2020-04-24 2020-12-29 Ferrer Medical Innovations, LLC Antiviral and virucidal nasal spray compositions and related treatment methods
US11013687B1 (en) 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
US12016941B2 (en) * 2022-03-03 2024-06-25 Profounda Health And Beauty Inc. Treatment composition for nasal and oral dryness, nosebleeds, and allergy symptoms
US20240000878A1 (en) * 2022-07-01 2024-01-04 Xlear, Inc. Methods for treatment and/or prevention of viral infections
FR3142656B1 (fr) 2022-12-05 2025-07-18 Antony Cheudjeu D-xylose dans la prévention ou le traitement du COVID19, du VIH et du diabète

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200940A (en) * 1966-11-19 1970-08-05 Takeda Chemical Industries Ltd A method for solubilising enduracidin and aqueous solutions thereof
NL7316612A (de) * 1972-12-05 1974-06-07
US4820506A (en) * 1987-05-01 1989-04-11 Research Foundation, State University Of New York Salivary stimulant
NL9000237A (nl) * 1990-01-31 1991-08-16 Re Novative Drugs For Dermatol Topicale farmaceutische composities voor de mondholte en vagina.
IT1270095B (it) * 1994-09-28 1997-04-28 Ibsa Inst Biochimique Sa Composizioni terapeutiche di condroitin solfato sotto forma di gel somministrabile per via orale
US5719196A (en) * 1996-07-24 1998-02-17 Leiras Oy Method of treating respiratory infections or complications derived therefrom in humans which includes oral administration of xylitol
EA199900194A1 (ru) * 1996-09-12 1999-12-29 Бичем Консьюмер Хелткер Гмбх Смитклайн Реминерализующая композиция
US6054143A (en) * 1998-03-24 2000-04-25 Jones; Alonzo H. Xylitol delivery

Also Published As

Publication number Publication date
US6054143A (en) 2000-04-25
AU748327B2 (en) 2002-05-30
EP1063885A1 (de) 2001-01-03
AU3202099A (en) 1999-10-18
EP1063885B1 (de) 2006-03-15
WO1999048361A1 (en) 1999-09-30
NO20004736D0 (no) 2000-09-22
CA2321819A1 (en) 1999-09-30
DE69930375D1 (de) 2006-05-11
NO331654B1 (no) 2012-02-13
DK1063885T3 (da) 2006-07-24
TR200002739T2 (tr) 2000-11-21
JP2002507548A (ja) 2002-03-12
PT1063885E (pt) 2006-05-31
CN1302183A (zh) 2001-07-04
EP1063885A4 (de) 2002-09-18
ES2161666T1 (es) 2001-12-16
ES2161666T3 (es) 2006-07-16
NO20004736L (no) 2000-10-11
IL138467A0 (en) 2001-10-31
NZ506557A (en) 2003-01-31
US6258372B1 (en) 2001-07-10
DE69930375T2 (de) 2006-10-19
CA2321819C (en) 2010-02-02

Similar Documents

Publication Publication Date Title
ATE320184T1 (de) Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
ES2124461T3 (es) Derivados de oxalilamino-benzofurano y de benzotienilo.
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ATE470446T1 (de) Neues verfahren und zusammensetzungen zur örtlichen behandlung von meniere-krankheit, tinnitus und/oder hörverlust
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
EE9900118A (et) H+,K+-ATPaasi inhibiitorite kasutamine ninapolüüpide ravimisel
EA200200137A1 (ru) Лечение невротических нарушений
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
SE9902267D0 (sv) New compounds
ATE309811T1 (de) Analgetikum aus schlangengift
DK1095059T3 (da) Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse
EA200400535A1 (ru) ПОДАВЛЕНИЕ ВИРУСОВ n-ДОКОСАНОЛОМ
PT1232173E (pt) Derivados do acido fusidico
DE69910787D1 (de) Neuartige, pharmazeutisch aktive verbindung
HRP20050580A2 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
ATE286728T1 (de) Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1063885

Country of ref document: EP